- Silk Road Medical (NASDAQ:SILK) disclosed positive data for its TCAR (TransCarotid Artery Revascularization) procedure in patients with blockages due to atherosclerosis in the carotid artery connecting the brain.
- The analysis covered more than 20K standard surgical risk patients undergoing carotid endarterectomy (CEA) and TCAR.
- Per the results, TCAR had statistically equivalent stroke and death outcomes to CEA, with a ninefold decline in cranial nerve injury (CNI) (2.7% vs 0.3%, p=<0.001), the company said.
- “The promise of safely preventing stroke while delivering benefits from a less-invasive approach is critically important as we consider an expanded patient population,” CEO of Silk Road Medical (SILK) remarked.
- "This first-ever large-scale, standard surgical risk analysis demonstrates that TCAR delivers on that promise.”
- The analysis was included today as a presentation at the Society for Vascular Surgery 2021 Vascular Annual Meeting (VAM) in San Diego, California.
As it prepares to expand the addressable market, Silk Road Medical (SILK) plans to include standard surgical risk patients for its TCAR procedure with new evidence.
Silk Road Medical presents data to support potential of its TCAR procedure
Recommended For You
About SILK Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| SILK | - | - |
| Silk Road Medical, Inc | ||